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Abstract
Background: Maspin is a unique member of the serine protease inhibitor superfamily and its expression is found
in myoepithelial cells of normal mammary glands; therefore, it has been considered to be a myoepithelial marker.
We previously reported that maspin was frequently expressed in biologically aggressive breast cancers. In turn,
triple-negative (TN) breast cancer is a subtype of tumor with aggressive clinical behavior and shows frequent
expression of basal markers. We hypothesized that maspin expression may be frequent and correlate with basal
rather than myoepithelial markers in TN breast cancer.
Methods: Paraffin-embedded 135 TN invasive ductal carcinoma tissue samples were immunohistochemically
investigated using the Dako Envision+ kit and primary antibodies for maspin, basal (CK5/6, EGFR, CK14) and
myoepithelial markers (p63, CD10). The correlation between maspin expression and relapse-free survival (RFS) was
investigated by the log-rank test.
Results: The positive rate for maspin was 85.9% and significantly correlated with younger age (P = 0.0015), higher
histological grade (P = 0.0013), CK5/6 positivity (P < 0.0001), CK14 positivity (P = 0.0034) and the basal-like subtype
defined by CK5/6, EGFR and CK14 positivity (P = 0.013). The positive rates for CK5/6, EGFR, CK14, CD10 and p63
were 59.2%, 48.9%, 34.1%, 17.8% and 12.6%, respectively. There was no significant correlation between maspin
expression and RFS.
Conclusions: The positive rate for maspin is the highest among known basal and myoepithelial markers, and
strongly correlates with basal markers in TN breast cancer. These results suggested that maspin could be a
candidate for a therapeutic target for TN breast cancer.
Introduction
Maspin is a unique member of the serine protease inhi-
bitor superfamily and it has been shown to have tumor
suppressive activity attributable to the inhibition of
breast cancer cell motility, invasion and metastasis [1].
Its expression is found in myoepithelial cells of normal
mammary glands; therefore, it has been considered to
be a myoepithelial marker, but its correlation with basal
markers, such as CK5/6, CK14 and epidermal growth
factor receptor (EGFR), in breast cancers remains to be
solved. On the other hand, triple-negative (TN) breast
cancer is a subtype of tumor with aggressive clinical
behavior which currently lacks effective targeted thera-
pies [2]; however, TN breast cancer encompasses a
remarkably heterogeneous group of tumors, and the
expression of basal markers identifies biologically and
clinically distinctive subgroups of TN tumors [2]. We
previously reported that maspin expression was an inde-
pendent poor prognostic indicator in invasive ductal
carcinoma (IDC) [3], and that its expression was up-
regulated during the progression of mammary ductal
carcinoma [4]. Additionally, Rakha et al. reported that
basal, not myoepithelial, phenotypes defined by CK5/6
and/or CK14 positivity had an independent value in pre-
dicting a poor clinical outcome in a large number of
invasive breast carcinomas [5]. Taken together, we
hypothesized that maspin expression could be frequent
and correlated with basal rather than myoepithelial mar-
kers in TN breast cancer. To explore this hypothesis, we
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correlation with established basal (CK5/6, EGFR, CK14)
and myoepithelial (p63, CD10) markers in TN breast
c a n c e r .I na d d i t i o n ,w ei n v e s tigated the relationship
between maspin expression and relapse-free survival
(RFS) in TN breast cancer.
Materials and methods
Paraffin-embedded tissue samples obtained from 135
TN breast cancer patients between Descember 2001 and
March 2006 were collected from Hakuaikai Sagara Hos-
pital (Kagoshima, Japan). All breast cancers were histo-
logically classified as IDC. The median age was 56.6
years (range: 27-91 years). Of 135 patients, follow-up
data were obtained from 126 patients. The median fol-
low-up time was 64.2 months (range: 3-136 months).
Breast cancer recurred in 27 patients (21.4%) during the
follow-up period. All patients, except for one, were his-
tologically examined for axillary lymph node involve-
ment, and 52 patients were histologically diagnosed as
node-positive. TN was defined as negative for ER and
PgR (cutoff 10%), as well as HER2 negative (Hercep test:
score 0, 1+, 2+). In cases that scored 2+, the absence of
HER2 gene amplification was confirmed by fluorescent
in situ hybridization analysis using the PathVysion kit
(Abbott-Vysis, Inc., Downers Grove, IL). Immunohisto-
chemistry was performed using the Dako Envision+ kit
in conjunction with the DAKO Autostainer according to
the instructions supplied by the manufacturer, as
described previously [6]. The primary antibodies used
and their cutoff values are shown in Table 1. The basal-
like subtype was defined by positive for CK5/6 and/or
EGFR [7]. Each staining result was assessed indepen-
dently by two pathologists (YO and YU). When the eva-
luations differed, final agreement was reached by
consensus. The patients and their tumor characteristics
were analyzed using the chi-square test. Actuarial curves
for RFS were calculated by the Kaplan-Meier technique.
RFS were calculated from the date of first surgery to the
date of clinical or pathological relapse. Differences in
RFS were tested with the log-rank test. All statistical
analyses were performed with a statistical software pack-
age (Dr SPSS version 11.0.1J; SPSS Japan Inc., Tokyo,
Japan). The cutoff for significance was taken as P = 0.05.
Results
Patient and tumor characteristics are summarized in
Table 2. The positive ratesf o rm a s p i n ,E G F R ,C K 5 / 6 ,
CK14, CD10 and p63 were 85.9% (116 cases), 48.9% (66
cases), 59.3% (80 cases), 34.1% (46 cases), 17.8% (24
cases) and 12.6% (17 cases), respectively (Table 2).
Expression of maspin significantly correlated with
younger age (P = 0.0015), higher histological grade (P =
0.0013), CK5/6 positivity (P < 0.0001) and CK14 positiv-
ity (P = 0.0034) (Table 3). The representative positive
staining pattern of maspin is shown in Figure 1. The
myoepithelial cells and stromal cells in mammary glands
served as internal positive and negative controls, respec-
tively. The basal-like subtype defined by CK5/6 and/or
EGFR expression was observed in 76.3% (103 of 135
cases). The positivity for maspin showed a slightly sig-
nificant correlation with t h eb a s a l - l i k es u b t y p e( P =
0.041) (Table 4). When defined by CK5/6 and/or EGFR
and/or CK14 positivity, the basal-like subtype was found
in 79.3% (107 of 135 cases) and the positivity for maspin
more significantly correlated with the basal-like subtype
(P = 0.013) (Table 4). The log-rank test showed that
only node metastases significantly correlated with RFS
(P < 0.0001). There was no significant correlation
between maspin expression and RFS (P = 0.204).
Discussion
In the current study, we restricted our analysis to IDC
of no special type to avoid any confounding effect of
special types of invasive breast cancer, such as lobular,
medullary and metaplastic carcinomas. Previous DNA
microarray and immunohistochemical analyses showed
that 80% to 90% of TN breast cancer were basal-like
subtypes and had clinical behavior similar to basal-like
behavior [2]. The positive rate for maspin in our study
was 85.9% of TN breast cancer, and the positive rate
was similar to that of basal-like subtypes in TN breast
Table 1 Souce, dilution, pretreatment and cutoff values of primary antibodies used
Antibody (clone) Manufacturer Dilution Pretreatment Cutoff values
Maspin (EAW24) Novocastra 1:200 Microwave ≧10% (positive)
CK5/6 (D5/16B4) Dako 1:50 Water bath ≧10% (positive)
CK14 (LL002) Novocastra 1:100 Water bath ≧10% (positive)
EGFR (EGFR.113) Novocastra 1:25 Microwave ≧10% (positive)
CD10 (56C6) Novocastra 1:50 Water bath ≧10% (positive)
p63 (4A4+Y4A3) LabVision 1:200 None ≧10% (positive)
ER (1D5) Dako 1:50 Water bath ≧10% (positive)
PgR (PgR636) Dako 1:800 Water bath ≧10% (positive)
HER2 Dako Prediluted (Hercep test) Water bath Score 3+ (positive)
Umekita et al. Diagnostic Pathology 2011, 6:36
http://www.diagnosticpathology.org/content/6/1/36
Page 2 of 4cancer. Although there is no consensus about the defini-
tion and method of identification of a basal-like subtype
in routine practice, tumors with a basal-like phenotype
were strongly associated with a high histological grade
in all classifications [2], which is similar to our previous
and present findings that maspin positivity strongly cor-
related with a high histological grade in IDC [3] and TN
breast cancer. There is no international consensus on
the precise complement of markers that defines a basal-
like subtype [2], but Nielsen’s definition, used in our
study, is currently considered one of the most pragmatic
and widely accepted definitions of basal-like breast can-
cer [7]. The single use of maspin positivity was able to
detect 89.3% (92 of 103) of basal-like subtypes defined
by Nielsen’s definition (CK5/6 and/or EGFR positivity).
Including CK14 in Nielsen’s definition, 89.7% (96 of
107) of the basal-like subtypes was detected by the
single use of maspin. Additionally, all 16 patients that
were CK5/6-positive and EGFR-positive, with low histo-
logical differentiation and younger age were maspin-
positive. Although the analyses of gene expression arrays
is required to conclude that maspin is a marker of the
basal-like subtype, our results suggested that maspin
could be a candidate for a basal marker in TN breast
cancer.
It has been hypothesized that maspin may regulate
gene transcription in response to cellular stress induced
by inflammation, tissue injury and remodeling [8], but
its function attributable to an aggressive phenotype in
some breast cancers remains to be resolved. We can
consider three possible explanations. One is that basal
differentiation could contribute to a more aggressive
phenotype [5,9]. The second is a high intracellular
Table 3 Association between maspin expression and
clinicopathological factors in triple-negative breast
cancer
Maspin expression
Positive (85.9%)
116 cases
Negative (14.1%)
19 cases
P-
value
Age (years)
≤50 50 1 0.0015
>50 66 18
Tumor size (mm)
≤20 41 3 0.091
>20 75 16
Lymph node
metastases
0 69 13 0.226
1-3 27 1
3< 20 4
Histological
grade
I 4 1 0.0013
II 19 10
III 93 8
EGFR
Positive 57 9 0.886
Negative 59 10
CK5/6
Positive 77 3 <0.0001
Negative 39 16
CK14
Positive 45 1 0.0034
Negative 71 18
CD10
Positive 19 5 0.293
Negative 97 14
p63
Positive 15 2 0.769
Negative 101 17
Table 2 Patients and tumor characteristics in triple-
negative breast cancer cohort
Parameters Number Percentage
Age (years)
≤50 51 37.8
>50 84 62.2
Tumor size (mm)
≤20 44 32.6
>20 91 67.4
Lymph node metastases
0 82 60.7
1-3 28 20.7
3< 24 17.8
Histological grade
I 5 3.7
II 29 21.5
III 101 74.8
Maspin
Positive 116 85.9
Negative 19 14.1
EGFR
Positive 66 48.9
Negative 69 51.1
CK5/6
Positive 80 59.3
Negative 55 40.7
CK14
Positive 46 34.1
Negative 89 65.9
CD10
Positive 24 17.8
Negative 111 82.2
p63
Positive 17 12.6
Negative 118 87.4
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its activity by non-covalent polymerization [10]. The
third is mutation of the maspin gene causing loss of
normal function of the maspin protein. Additionally, it
has been reported that two intriguing genes upregulated
by maspin re-expression were the E2F transcription fac-
tor 1 (E2F1) and the naturally occurring BRCA1 splice
variant BRCA1b, and that maspin may play an impor-
tant role in response to DNA damage at the level of
cell-cycle regulation and cellular proliferation [8]. On
the other hands, the majority of BRCA1-associated
breast cancers is TN and expresses basal cytokeratins
[11]. Therefore the elucidation of more precise molecu-
lar mechanisms between maspin and BRCA1 may be
one of the important targets of future research. It could
be argued that instead of identifying descriptive and
prognostic molecular subgroups, such as basal-like
within TN breast cancer, it would be more clinically
relevant to identify patients whose TN tumors are sensi-
tive to specific chemotherapy agents and targeted thera-
pies [12]. It is important for the development of
targeted therapies to elucidate the role and function of
maspin in TN breast cancer.
Acknowledgements
We are grateful to Ms Shinobu Haraguchi and Ms Yoshie Jitouhou for their
excellent technical assistance.
Author details
1Department of Molecular and Cellular Pathology, Field of Oncology,
Kagoshima University Graduate School of Medical and Dental Sciences 8-35-
1, Sakuragaoka, Kagoshima 890-8544, Japan.
2Hakuaikai Sagara Hospital,
Kagoshima, 3-31, Matsubara, Kagoshima 892-0833, Japan.
Authors’ contributions
YU designed the study, evaluated immunohistochemistry, performed
statistical analysis and wrote the manuscript. YO interpreted the data and
evaluated immunohistochemistry. MS performed immunohistochemical
experiments. YR, YS, YS and ST participated in the sampling of clinical data.
AT performed critical reading of manuscript and supervision. All authors
have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 6 January 2011 Accepted: 16 April 2011
Published: 16 April 2011
References
1. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveau M, Sheng S, Rafidi K,
Seftor E, Sagar R: Maspin, a serpin with tumor-suppressing activity in
human mammary epithelial cells. Science 1994, 263:526-529.
2. Rakha EA, Ellis IO: Triple-negative/basal-like breast cancer: review.
Pathology 2009, 41:40-47.
3. Umekita Y, Ohi Y, Sagara Y, Yoshida H: Expression of maspin predicts poor
prognosis in breast cancer patients. Int J Cancer 2002, 100:452-455.
4. Umekita Y, Yoshida H: Expression of maspin is up-regulated during the
progression of mammary ductal carcinoma. Histopathology 2003,
42:541-545.
5. Rakha EA, Putti TC, El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH,
Robertson JF, Ellis IO: Morphological and immunophenotypic analysis of
breast carcinomas with basal and myoepithelial differentiation. J Pathol
2006, 208:495-506.
6. Umekita Y, Souda M, Ohi Y, Sagara Y, Rai Y, Takahama T, Yoshida H:
Expression of wild-type estrogen receptor β protein in human breast
cancer: Specific correlation with HER2/neu overexpression. Pathol Int
2006, 56:423-427.
7. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-
Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown Am,
Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical
characterization of the basal-like subtype of invasive breast carcinoma.
Clin Cancer Res 2004, 10:5367-5374.
8. Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJC: Biological function of
maspin. J Cell Phisiol 2006, 209:617-624.
9. Jones C, Nonni AV, Fuitord L, Merrett S, Chaggar R, Eusebi V, Lakhani SR:
CGH analysis of ductal carcinoma of the breast with basaloid/
myoepithelial cell differentiation. Br J Cancer 2001, 85:422-427.
10. Liu T, Pemberton PA, Robertson AD: Three-state unfolding and self
association of maspin, a tumor-suppressing serpin. J Biol Chem 1999,
274:29628-29632.
11. Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: A critical review. J
Clin Oncol 2008, 26:2568-2581.
12. Foulkes WD, Smith IE, Reis-Filho JS: Triple-nagtive breast cancer. New Engl
J Med 2010, 363:1938-1948.
doi:10.1186/1746-1596-6-36
Cite this article as: Umekita et al.: Maspin expression is frequent and
correlates with basal markers in triple-negative breast cancer. Diagnostic
Pathology 2011 6:36.
Figure 1 Immunohistochemical detection of maspin in triple-
negative invasive ductal carcinoma. Cytoplasmic staining was
noted in carcinoma cells, and stromal cells were negatively stained.
Table 4 Association between maspin expression and
basal-like subtype in triple-negative breast cancer
Maspin expression
Positive (85.9%)
116 cases
Negative (14.1%)
19 cases
P-
value
CK5/6 and/or EGFR
Positive 92 11 0.041
Negative 24 8
CK5/6 and/or EGFR
and/or CK14
Positive 96 11 0.013
Negative 20 8
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